GAM Holding AG lowered its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 2.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 74,300 shares of the biopharmaceutical company’s stock after selling 1,500 shares during the period. GAM Holding AG owned about 0.19% of Ultragenyx Pharmaceutical worth $5,271,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Pacer Advisors Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $100,000. First Mercantile Trust Co. increased its stake in shares of Ultragenyx Pharmaceutical by 1.7% in the third quarter. First Mercantile Trust Co. now owns 2,339 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 39 shares during the period. DIAM Co. Ltd. purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $177,000. BlackRock Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 58.5% in the second quarter. BlackRock Inc. now owns 3,973 shares of the biopharmaceutical company’s stock worth $194,000 after buying an additional 1,467 shares during the period. Finally, Creative Planning increased its stake in shares of Ultragenyx Pharmaceutical by 16,700.0% in the second quarter. Creative Planning now owns 4,200 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 4,175 shares during the period. Institutional investors own 95.51% of the company’s stock.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) traded down 7.01% during mid-day trading on Wednesday, hitting $78.29. The stock had a trading volume of 888,601 shares. The firm’s 50-day moving average price is $69.53 and its 200 day moving average price is $64.95. The stock’s market cap is $3.20 billion. Ultragenyx Pharmaceutical Inc. has a 12-month low of $46.52 and a 12-month high of $117.12.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($1.64) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.53) by $0.11. During the same period in the prior year, the company posted ($1.03) earnings per share. Equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post ($6.15) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “GAM Holding AG Sells 1,500 Shares of Ultragenyx Pharmaceutical Inc. (RARE)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be read at https://www.thecerbatgem.com/2016/11/30/gam-holding-ag-sells-1500-shares-of-ultragenyx-pharmaceutical-inc-rare.html.

A number of equities research analysts have recently weighed in on RARE shares. Jefferies Group set a $109.00 price target on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Sunday, September 18th. Credit Suisse Group AG reiterated a “buy” rating and issued a $101.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, September 14th. Leerink Swann reiterated a “buy” rating and issued a $86.00 price target on shares of Ultragenyx Pharmaceutical in a report on Thursday, August 25th. Cowen and Company reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 9th. Finally, JPMorgan Chase & Co. set a $110.00 price target on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Monday, August 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $95.37.

In other news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction that occurred on Friday, October 14th. The stock was sold at an average price of $63.02, for a total value of $1,260,400.00. Following the completion of the transaction, the chief executive officer now directly owns 480,632 shares of the company’s stock, valued at approximately $30,289,428.64. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Shalini Sharp sold 12,000 shares of the stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $61.40, for a total value of $736,800.00. Following the completion of the transaction, the chief financial officer now directly owns 57,387 shares of the company’s stock, valued at $3,523,561.80. The disclosure for this sale can be found here. 10.10% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.